Alkermes (ALKS) to Release Earnings on Wednesday

Alkermes (NASDAQ:ALKS) is expected to post its quarterly earnings results before the market opens on Wednesday, February 12th. Analysts expect Alkermes to post earnings of $0.80 per share and revenue of $379.74 million for the quarter.

Alkermes Stock Performance

Shares of Alkermes stock opened at $31.39 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The business’s 50 day moving average price is $29.98 and its 200 day moving average price is $28.49. The company has a market cap of $5.08 billion, a price-to-earnings ratio of 16.10, a PEG ratio of 1.68 and a beta of 0.49. Alkermes has a one year low of $22.90 and a one year high of $32.88.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ALKS. The Goldman Sachs Group dropped their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, October 25th. HC Wainwright restated a “neutral” rating and issued a $37.00 target price on shares of Alkermes in a research report on Friday, October 25th. Cantor Fitzgerald lowered their price target on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Mizuho boosted their price objective on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $37.00 target price (down previously from $38.00) on shares of Alkermes in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Insider Buying and Selling

In related news, SVP Christian Todd Nichols sold 5,208 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the transaction, the senior vice president now directly owns 60,703 shares of the company’s stock, valued at $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Craig C. Hopkinson sold 100,918 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now owns 44,290 shares in the company, valued at $1,419,494.50. This represents a 69.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 238,185 shares of company stock worth $7,498,117. Company insiders own 4.89% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.